Nanoalbumon (Human Serum Albumin)

Human serum albumin is the main protein responsible for maintaining plasma oncotic pressure. When infused, it stays largely within the vascular space, pulling water from the interstitial fluid into the bloodstream, thereby expanding plasma volume and supporting circulatory stability.

The dose of Nanoalbumon is individualized by the prescribing clinician based on the patient’s weight, clinical condition, and target plasma albumin level. Dosage calculations consider the severity of volume loss and the desired oncotic effect.

Human serum albumin is a naturally occurring protein, and limited data suggest it does not cross the placenta in harmful amounts. However, because safety data are insufficient, the product should be used in pregnancy or lactation only if clearly needed and after risk‑benefit assessment by the healthcare provider.

To order Nanoalbumon, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if required) and necessary import documentation.

Nanoalbumon (human serum albumin) provides oncotic support similar to other albumin products but differs from synthetic colloids such as hydroxyethyl starch, which have distinct safety profiles. Albumin is a natural protein with a lower risk of coagulopathy and renal impairment, making it a preferred choice in many clinical scenarios.

Nanoalbumon should be stored at 2‑8 °C in a refrigerator, protected from light, and must not be frozen or shaken. Before administration, inspect the solution for particulate matter or discoloration and allow it to reach room temperature if required by the infusion protocol.

Nanoalbumon is administered intravenously, typically as an infusion over a period determined by the prescriber. The infusion rate may be adjusted based on the patient’s hemodynamic response, and vital signs should be monitored throughout the administration.

Serious risks include anaphylactic reactions, volume overload leading to pulmonary edema, hemolysis, and rare cases of sepsis from contaminated product. Prompt recognition of these events and immediate medical intervention are essential.

Nanoalbumon is contraindicated in patients with known hypersensitivity to human serum albumin or any component of the formulation. Caution is also advised for individuals with severe heart failure, uncontrolled hypertension, or active pulmonary edema, where additional volume may be harmful.